

REMARKS/ARGUMENTS

Claims 1-14 and 48-49 are presently pending. Claim 1 is amended herein.

Claim Amendments

Claim 1 is amended to clarify that “pretargeting an enzyme to a mammalian site” comprises, “(i) administering a bispecific antibody or fragment, wherein one arm of the bispecific antibody is targeted against a target site antigen and a second arm is targeted against a low molecular weight hapten that is conjugated to said enzyme,” and “(ii) administering a low molecular weight hapten that is conjugated to said enzyme.” Support for the amendment may be found in the published Specification (No. 20020114808) at least at Paragraph [0019] and Examples 3-7.

Claim Rejections – 35 U.S.C. § 112

Claims 1-14 and 48-49 are rejected under 35 U.S.C. 112, 2nd paragraph as incomplete for omitting essential steps. The Action asserts that the omitted steps are: (1) administration of a bispecific antibody or antibody thereof [*sic*], wherein one arm of the bispecific antibody is targeted against a target site antigen and a second arm is targeted against a low molecular weight hapten that is conjugated to said enzyme; and (2) administration of a low molecular weight hapten that is conjugated to an enzyme.”

Claim 1 is amended herein to clarify that “pretargeting an enzyme to a mammalian site” comprises, “(i) administering a bispecific antibody or fragment, wherein one arm of the bispecific antibody is targeted against a target site antigen and a second arm is targeted against a low molecular weight hapten that is conjugated to said enzyme,” and “(ii) administering a low molecular weight hapten that is conjugated to said enzyme.”

Applicants submit that the amendment overcomes the rejection. Reconsideration and withdrawal of the rejection is respectfully requested.

Double Patenting

Claims 1, 4-5 and 11 are rejected on the ground of nonstatutory obviousness-type double patenting over claims 1, 4-5, 16-18 and 24-25 of U.S. Patent No. 6,962,702.


Submitted herewith is a terminal disclaimer over U.S. Patent No. 6,962,702.

Conclusion

For the reasons stated above, Applicants submit that the amended claims are in condition for allowance and request withdrawal of the rejections.

Respectfully submitted,

Dated: April 16, 2007



Richard A. Nakashima
Reg. No. 42,023